title: [Nine-valent HPV vaccine - new generation of HPV vaccine].
abstract: OBJECTIVE
  To evaluate current knowledge about new generation of HPV vaccine - nine-valent vaccine Gardasil9.
  
  
  METHODS
  Review article.
  
  
  RESULTS
  The nine-valent vaccine against HPV 6/11/16/18/31/33/45/52/58 could improve efficacy of quadrivalent vaccine from 70 to 90 percent for cervical cancer. In addition this vaccine has covered around85-90% of HPV-related vulvar, vaginal and anal cancers. Efficacy and immunogenicity against HPV 6/11/16/18 is the same as for quadrivalent vaccine. Efficacy against HPV 31/33/45/52/58 associated lesions is 97%.
authors.forename: T
authors.initials: T
authors.lastname: Fait
authors.forename: V
authors.initials: V
authors.lastname: Dvořák
authors.forename: R
authors.initials: R
authors.lastname: Pilka
mesh_terms: D001005:Anus Neoplasms / Q000517:prevention & control* / Q000821:virology; D005260:Female; D006801:Humans; D008297:Male; D030361:Papillomavirus Infections / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000627:therapeutic use*; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control* / Q000821:virology; D014625:Vaginal Neoplasms / Q000517:prevention & control*; D014846:Vulvar Neoplasms / Q000517:prevention & control*
chemical_list: D053918:Papillomavirus Vaccines
keywords: HPV infection; nine-valent HPV vaccine.; prevention